U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Cover of Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet].

Show details

5CONCLUSIONS

The review included two open-label RCTs, EINSTEIN DVT and EINSTEIN PE. The two trials compared the anticoagulation effects of rivaroxaban and enoxaparin/VKA for the treatment and recurrence prevention of DVT and or PE. Overall survival in the two trials showed similar incidence of all-cause mortality between the two study treatments. The EINSTEIN DVT trial showed that rivaroxaban was non-inferior to enoxaparin and a VKA for the treatment of DVT in patients without symptomatic PE. However, although rivaroxaban was found to be non-inferior to enoxaparin/VKA in the treatment and prevention of recurrent VTE based on the pre-specified NIM for EINSTEIN PE, there is uncertainty around the NIM used. CDR re-evaluation of the margin suggests a tighter and more conservative one than that used in EINSTEIN PE. Rivaroxaban appeared similar to enoxaparin/VKA with respect to clinically relevant harms such as bleeding and SAEs. The incidence of AEs did not differ significantly between treatment groups in either trial.

Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK344335
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...